Tune into our latest webinar, which details the current state of precision medicine in lung cancer, and its clinical applications. Nathan Merrill, University of Michigan, Ann Arbor, USA, presents his work on a precision medicine-based platform, which is used to screen patient-derived material directly from the operating room, and what this means for the future of lung cancer treatment.
Merrill describes the study carried out by his department, presenting on the assay reproducibility, and translating the results of this study to improve clinical practice.
Themes covered include:
- the state of precision medicine in lung cancer;
- uses of the precision medicine-based platform;
- precision medicine-based platform in lung cancer; and
- future directions.
Speaker:
Nathan Merrill is Research Investigator in the Department of Internal Medicine at the University of Michigan, Ann Arbor, USA. He is particularly interested in the identification of biomarkers of drug efficacy in highly aggressive forms of cancer, including EML4-ALK fusion lung cancer, muscle-invasive bladder cancer, and triple-negative breast cancer. Currently, Merrill is working on utilising a novel platform to improve translational science and patient treatment.
Merrill’s work aims to encourage a more integrative and personalised approach to treating patients, in which individual tumours are characterised and screened, in order to pair the patient with the correct drug for them.
